Bioventus reiterates 2026 guidance after FDA device reclassification May 21, 2026 05:14PM
Bioventus Inc. (BVS) Tops Q1 EPS by 5c ; Offers Guidance May 6, 2026 07:34AM
Bioventus Inc (BVS) PT Raised to $16 at Craig-Hallum: "stock was and is far too cheap" Mar 6, 2026 09:55AM
Bioventus Inc. (BVS) Tops Q4 EPS by 4c ; Offers Guidance Mar 5, 2026 07:05AM
Barrington Research Starts Bioventus Inc (BVS) at Outperform Feb 9, 2026 07:57AM


Nov 4, 2025 07:35AM Bioventus Inc. (BVS) Tops Q3 EPS by 4c ; Offers Guidance
Aug 11, 2025 07:02AM Cantor Fitzgerald Reiterates Overweight Rating on Bioventus Inc (BVS)
Aug 6, 2025 07:10AM Bioventus Inc. (BVS) Reports In-Line Q2 EPS ; Offers Guidance
Jul 30, 2025 07:31AM Bioventus receives FDA clearance for two nerve stimulation devices
Jul 7, 2025 06:41AM Cantor Fitzgerald Starts Bioventus Inc (BVS) at Overweight
May 6, 2025 07:34AM Bioventus Inc. (BVS) Tops Q1 EPS by 4c
Apr 1, 2025 06:40AM Canaccord Genuity Reiterates Buy Rating on Bioventus Inc (BVS)
Mar 11, 2025 07:34AM Bioventus Inc. (BVS) reported Q4 Revenue ; Offers Guidance
Jan 2, 2025 10:27AM Canaccord Genuity Reiterates Buy Rating on Bioventus Inc (BVS)
Nov 6, 2024 07:38AM Bioventus Inc (BVS) PT Raised to $15 at Canaccord Genuity
Nov 5, 2024 07:37AM Bioventus Inc. (BVS) Misses Q3 EPS by 9c ; Offers Guidance
Oct 25, 2024 04:17PM Bioventus (BVS) Files $200M Mixed Shelf
Oct 1, 2024 01:38PM Canaccord Genuity Reiterates Buy Rating on Bioventus Inc (BVS)
Aug 6, 2024 07:34AM Bioventus Inc. (BVS) Tops Q2 EPS by 12c; offers guidance